Kenvue’s Stock Decline Is a ‘Solid’ Buying Opportunity

Norge Nyheter Nyheter

Kenvue’s Stock Decline Is a ‘Solid’ Buying Opportunity
Norge Siste Nytt,Norge Overskrifter
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 97%

Deutsche Bank Research analyst Steve Powers upgraded Kenvue to Buy from Hold over the weekend.

Kenvue shares have fallen recently as investors have become concerned about the company’s exposure to lawsuits over its pain reliever Tylenol.

Kenvue , which was recently spun off from Johnson & Johnson , faces lawsuits claiming Tylenol caused neurological disorders in children whose mothers took the medication while pregnant. They say the company is at fault for not including a warning about the possible risks on the bottle’s label. The stock was down 2.7% in August, and J.P. Morgan analyst Andrea Teixeira said in a Friday note the decline provides a buying opportunity. Teixeira rates the stock as Overweight with a $29 price target.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

MarketWatch /  🏆 3. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

1 Stock to Buy, 1 Stock to Sell This Week: Oracle, Apple1 Stock to Buy, 1 Stock to Sell This Week: Oracle, AppleStocks Analysis by Investing.com (Jesse Cohen) covering: Oracle Corporation, Apple Inc, Oracle Corp, Apple Inc DRC. Read Investing.com (Jesse Cohen)'s latest article on Investing.com
Les mer »

David Peterson’s solid outing undone by Mets bullpen in loss to TwinsDavid Peterson’s solid outing undone by Mets bullpen in loss to TwinsThe Mets matched their season low by falling 13 games below .500.
Les mer »

Rangers’ Jack Leiter solid again in longest outing since return from developmental listRangers’ Jack Leiter solid again in longest outing since return from developmental listLeiter pitched five innings, allowed two earned runs on one hit and two walks and struck out five.
Les mer »

San Diego's Crinetics releases solid results for drug that treats deadly rare diseaseSan Diego's Crinetics releases solid results for drug that treats deadly rare diseaseIf approved by the FDA, Paltusotine would be the company's first drug on the market. It treats a rare disorder caused by a tumor on a person's pituitary gland that causes the release of too much growth hormone.
Les mer »

‘The Nun II’ Scares Up Solid Global Box Office Debut‘The Nun II’ Scares Up Solid Global Box Office DebutEven within the larger Conjuring Universe, the Nun remains especially popular.
Les mer »

‘The Nun II’ conjures a solid $32.6 million to top box office‘The Nun II’ conjures a solid $32.6 million to top box officeLike many horrors before it, bad reviews didn’t scare off moviegoers from buying tickets for “The Nun II.”
Les mer »



Render Time: 2025-03-04 17:10:31